According to today’s article on Bloomberg Quint, “Moderna Chief Sells More Shares Ahead of Urgent Vaccine Filing.”
Shares of Moderna jumped 2.44% to $99.99 at 13:09 EST on Monday, after two consecutive sessions in a row of gains. The Nasdaq Stock Market is sliding 0.04% to $11,850.30, following yesterday’s downward trend, on what up until now seems, a somewhat negative trend trading session on today.
Moderna’s last close was $97.61, below its 52-week high of $103.20.
Moderna’s sales growth is 1216.8% for the current quarter and 2299% for the next. The company’s growth estimates for the current quarter is a negative 67.6% and positive 142.9% for the next.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s stock is valued at $99.99 at 13:09 EST, under its 52-week high of $103.20 and way higher than its 52-week low of $17.68.
Moderna’s worth is way above its 50-day moving average of $76.35 and way above its 200-day moving average of $69.55.
According to Bloomberg Quint on Thu Nov 19, “Moderna Vaccine Production Is Gearing Up, Partner Lonza Says.”
According to Bloomberg Quint on Fri Nov 20, “EU Could Approve BioNTech, Moderna Vaccines in December.”